FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and represents a pharmaceutical combination for treating in pain conditions in the form of a solid dosage form for oral administration, characterised by the fact that it contains Mirtazapine 5 mg - 50 mg; Tizanidine 0.5 - 6 mg in ratio 20:1-5:1, and a pharmaceutically acceptable carrier.
EFFECT: invention provides creating an effective agent for preventing or treating a pain condition well-tolerated by patients.
6 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF MIRTAZAPINE AND TIZANIDINE FOR USE IN PAIN DISORDERS | 2019 |
|
RU2736713C1 |
| METHOD OF TREATING VERTEBRAL PAIN SYNDROMES | 2014 |
|
RU2578962C1 |
| COMBINATIONS OF PALMITOYLETHANOLAMIDE FOR TREATING CHRONIC PAIN | 2018 |
|
RU2701720C1 |
| COMBINATION OF FLUPIRTINE AND CYCLOBENZAPRINE FOR TREATMENT OF PAIN SYNDROMES | 2017 |
|
RU2680244C1 |
| METHOD OF TREATING MUSCULAR TONIC DISORDERS OF CHEWING MUSCULATURE | 2019 |
|
RU2731694C1 |
| COMBINATION OF MEDICINAL AGENTS COMPRISING MIRTAZAPINE FOR TREATMENT OF DEPRESSION AND ASSOCIATED DISORDERS | 2001 |
|
RU2268725C2 |
| ISOVALERAMIDE AS ANTISPATIC AND ANTICONVULSANT AGENT, EXTRACT FROM PLANT OF VALERIANACEACE FAMILY AND HOP AS AGENT FOR TREATMENT OF SPASTICITY SYMPTOM AND METHOD FOR ELIMINATION OF THIS SYMPTOM, METHOD FOR TREATMENT OF PATHOLOGY ELIMINATED BY CENTRALLY-MEDIATED REDUCING MUSCLE TONUS | 1997 |
|
RU2232016C2 |
| APPLICATION OF TIZANIDINE AS DRUG-INDUCED PARKINSONISM CORRECTOR | 2008 |
|
RU2393860C2 |
| ORGANIC COMPOUNDS | 2018 |
|
RU2777366C2 |
| (R)-PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | 2014 |
|
RU2695607C2 |
